Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Sheldon Koenig, President and CEO,...
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
December 13, 2023 16:00 ET
|
Esperion Therapeutics, Inc.
– Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use – – Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with...
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
November 13, 2023 10:30 ET
|
Esperion Therapeutics, Inc.
– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and...
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
November 11, 2023 11:00 ET
|
Esperion Therapeutics, Inc.
– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis – ANN ARBOR, Mich., Nov. 11, 2023 (GLOBE...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 09, 2023 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 8, 2023, the Company granted 18 new employees 141,800 restricted stock units (RSUs)...
Esperion Reports Third Quarter 2023 Financial Results
November 07, 2023 06:00 ET
|
Esperion Therapeutics, Inc.
– Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained...
Esperion to Participate in Jefferies London Healthcare Conference
October 31, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the Jefferies London Healthcare Conference. Sheldon Koenig, President and Chief...
Esperion to Report Third Quarter 2023 Financial Results on November 7
October 24, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2023 financial results before the market opens on Tuesday, November 7, 2023....
American College of Cardiology Program to Increase Cholesterol Screenings
September 12, 2023 10:15 ET
|
Esperion Therapeutics, Inc.; The American College of Cardiology
Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL WASHINGTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American...
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig,...